Study of ARC-520 in Patient With Chronic Hepatitis B Virus
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 14 Apr 2016
At a glance
- Drugs ARC 520 (Primary) ; Entecavir; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Arrowhead Pharmaceuticals
- 13 Aug 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 01 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 15 Dec 2014 According to a media release, Arrowhead Research Corporation plans to submit additional clinical trial authorization applications with regulatory authorities in various jurisdictions in Europe and Asia.